FUDANZHANGJIANG<08231> - Results Announcement (Q3, 2004, Summary)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. announced on 10/11/2004:
(stock code: 08231 )
Year end date :31/12/2004
Currency :RMB
Auditors' report :N/A
3rd Quarterly Report Reviewed by :Audit Committee
Important Note :
This result announcement form only contains extracted information from
and should be read in conjunction with the detailed results announcement
of the issuer, which can be viewed on the GEM website at
http://www.hkgem.com
(Unaudited) (Unaudited)
Current Last Corresponding
Period Period
from 01/01/2004 from 01/01/2003
to 30/09/2004 to 30/09/2003
RMB'000 RMB'000
Turnover : 9,382 6,546
Profit/(Loss) from Operations : (14,503) (13,447)
Finance cost : 0 0
Share of Profit/(Loss) of Associates : (1,579) (956)
Share of Profit/(Loss) of Jointly
Controlled Entites : N/A N/A
Profit/(Loss) after Taxation & MI : (13,409) (14,135)
% Change Over the Last Period : N/A
EPS / (LPS)
Basic (in dollar) : (RMB 0.0189) (RMB 0.0199)
Diluted (in dollar) : N/A N/A
Extraordinary (ETD) Gain/(Loss) : 0 0
Profit (Loss) after ETD Items : (13,409) (14,135)
3rd Quarter Dividends per Share : NIL NIL
(specify if with other options) : N/A N/A
B/C Dates for 3rd Quarter Dividends : N/A
Payable Date : N/A
B/C Dates for (-) General Meeting : N/A
Other Distribution for Current Period : NIL
B/C Dates for Other Distribution : N/A
(bdi: both days inclusive)
For and on behalf of
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Signature :
Name : Wang Rui
Title : Company Secretary
Responsibility statement
The directors of the Company (the "Directors") as at the date hereof
hereby collectively and individually accept full responsibility for the
accuracy of the information contained in this results announcement form
(the "Information") and confirm, having made all reasonable inquiries,
that to the best of their knowledge and belief the Information are
accurate and complete in all material respects and not misleading and
that there are no other matters the omission of which would make the
Information herein inaccurate or misleading.The Directors acknowledge
that the Stock Exchange has no responsibility whatsoever with regard to
the Information and undertake to indemnify the Exchange against all
liability incurred and all losses suffered by the Exchange in connection
with or relating to the Information.
Remarks:
1. Basis of preparation
The consolidated financial statements have been prepared in
accordance with the International Accounting Standards,
accounting principles generally accepted in Hong Kong, and
the disclosure requirements of the Hong Kong Companies
Ordinance. The principal accounting policies adopted are
consistent with those used in the preparation of the Group¡¦s
financial information included in the accountants¡¦ report as
set out in the prospectus published on 31 July 2002 in connection
with the placing of H shares of the Company on the GEM.
The results are unaudited but have been reviewed by the audit
committee of the Group.
2. Financial review
For the nine months ended 30 September 2004,the Group recorded
a turnover of approximately RMB9,382,000, of which,
RMB4,200,000 (or 45% of the total turnover) came from the income
of technology transfer, and the rest which is approximately
RMB5,182,000 (or 55% of the total turnover) was derived from
the sale of diagnostic products and the provision of auxiliary
service. In comparison, the entire turnover of approximately
RMB6,546,000 for the same period last year was obtain from
the sale of diagnostic reagents.
The total expenses of the Group for the nine months ended 30
September 2004 amounted to approximately RMB28,796,000 and
the loss attributable to shareholders was approximately
RMB13,409,000. The corresponding figures for the same period
last year were RMB24,838,000 and RMB14,135,000 respectively.
3. Loss per share
The calculation of the loss per share for the three months
and nine months ended 30 September 2004
was based on the unaudited loss attributable to shareholders
of approximately RMB5,270,000 and RMB13,409,000 respectively
(three months and nine months ended 30 September 2003: unaudited
loss attributable to shareholders of approximately
RMB7,304,000 and RMB14,135,000 respectively) and total of
710,000,000 shares in issue during the three months and nine
months ended 30 September 2004 (2003: 710,000,000 shares).
Diluted loss per share has not been calculated for the three
months and nine months ended 30 September 2004 and 30 September
2003 as there was no dilutive potential ordinary share during
those periods.
|